EUVIMEDEUVIMED entdecken
Crossref

Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes

Xiang-Quan Kong iD, Juan Zhang, Xiao-Fei Gao iD, Zhi-Mei Wang, Peng Ye, Jun-Jie Zhang iD, Shao-Liang Chen iD

Catheterization and Cardiovascular Interventions · 2024-11 · 104 (6) · 1275-1280

DOI: 10.1002/ccd.31193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 27.08.2024. Verfasst von Xiang-Quan Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis, Prosthesis Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Jiangsu Health Committee, Nanjing Health Committee, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) for the treatment of aortic regurgitation (AR).

Methods

From September 2019 to February 2022, 62 patients who underwent transfemoral TAVI procedure for pure, symptomatic severe AR with the VitaFlow system were enrolled in the current study. The outcomes were assessed according to the Valve Academic Research Consortium 3 criteria. Procedural results and clinical outcomes for 1 year were analyzed.

Results

The mean age was 71.56 ± 7.34 years and 58.1% were male. The mean Society of Thoracic Surgeons score was 5.44 ± 3.22%. The device success rate was 79.0%. Only one patient was converted to open surgery. The in‐hospital mortality rate was 1.6%. The 1‐year all‐cause mortality rate was 6.5%. The new permanent pacemaker implantation rate was 29.0% in‐hospital and 30.7% at 1‐year follow‐up. The second valve implantation rate was 14.5%. No patient developed more than moderate paravalvular leakage during follow‐up. The mean ejection fraction improved from 54.05 ± 10.83% at baseline to 59.32 ± 8.70% ( p < 0.001 compared with baseline) at 12 months. Left ventricular end‐diastolic diameter decreased from 61.62 ± 5.58 mm at baseline to 55.20 ± 4.51 mm ( p < 0.001 compared with the baseline) at 12 months.

Conclusions

Transfemoral TAVI procedure shows efficacy in treating patients with severe pure native AR. The safety is improved with the development of the VitaFlow system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve InsufficiencyTranscatheter Aortic Valve ReplacementHeart Valve ProsthesisProsthesis DesignAortic ValveHospital MortalitySeverity of Illness IndexRecovery of FunctionVentricular Function, LeftHumansMaleFemaleAgedTreatment OutcomeTime FactorsRisk FactorsAged, 80 and overRetrospective StudiesRisk AssessmentMiddle AgedHemodynamicsCardiac Pacing, Artificial

Stichwörter der Autor:innen

VitaFlow systemaortic regurgitationdevice successtranscatheter aortic valve implantation

Autor:innen und Institutionen

  • Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Xiang-Quan Kong, Xiao-Fei Gao, Jun-Jie Zhang, Shao-Liang Chen

Förderung

  • Jiangsu Health Committee
  • Nanjing Health Committee
  • National Natural Science Foundation of China
  • Six Talent Peaks Project of Jiangsu Province
  • National Key R&D Program of China

Zitieren

APA

Kong, X. Q., Zhang, J., Gao, X. F., Wang, Z. M., Ye, P., Zhang, J. J., & Chen, S. L. (2024). Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes. Catheterization and Cardiovascular Interventions, 104(6), 1275-1280. https://doi.org/10.1002/ccd.31193

Vancouver

Kong XQ, Zhang J, Gao XF, Wang ZM, Ye P, Zhang JJ, et al. Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes. Catheterization and Cardiovascular Interventions. 2024;104(6):1275-1280. doi:10.1002/ccd.31193

BibTeX
@article{Kong2024,
  author = {Kong, Xiang-Quan and Zhang, Juan and Gao, Xiao-Fei and Wang, Zhi-Mei and Ye, Peng and Zhang, Jun-Jie and Chen, Shao-Liang},
  title = {Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  volume = {104},
  number = {6},
  pages = {1275--1280},
  doi = {10.1002/ccd.31193}
}
Kostenlos starten →